(Q43005857)

12 November 2017

Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in Japan (English)

1 reference

12 November 2017

chronic myeloid leukemia

0 references

1 reference

7

Chiaki Nakaseko

1 reference

12 November 2017

20

Noriko Usui

1 reference

12 November 2017

Tadashi Nagai

1

1 reference

12 November 2017

Jin Takeuchi

2

1 reference

12 November 2017

Nobuaki Dobashi

3

1 reference

12 November 2017

Yuzuru Kanakura

4

1 reference

12 November 2017

Shuichi Taniguchi

5

1 reference

12 November 2017

Koji Ezaki

6

1 reference

12 November 2017

Akira Hiraoka

8

1 reference

12 November 2017

Masaya Okada

9

1 reference

12 November 2017

Yasushi Miyazaki

10

1 reference

12 November 2017

Toshiko Motoji

11

1 reference

12 November 2017

Masaaki Higashihara

12

1 reference

12 November 2017

Norifumi Tsukamoto

13

1 reference

12 November 2017

Hitoshi Kiyoi

14

1 reference

12 November 2017

Shinji Nakao

15

1 reference

12 November 2017

Katsuji Shinagawa

16

1 reference

12 November 2017

Ryuzo Ohno

17

1 reference

12 November 2017

Tomoki Naoe

18

1 reference

12 November 2017

Kazunori Ohnishi

19

1 reference

12 November 2017

25 June 2010

1 reference

International Journal of Hematology

12 November 2017

1 reference

12 November 2017

92

1 reference

12 November 2017

1

1 reference

12 November 2017

111-117

1 reference

https://scigraph.springernature.com/pub.10.1007/s12185-010-0621-x

12 November 2017

0 references

cites work

Effects of lower dose of imatinib to CML patients

1 reference

12 December 2020

Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: a study in nagasaki prefecture, Japan

1 reference

12 December 2020

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

12 December 2020

Current and future perspectives on the TARGET system: the registration system for Glivec established by the JSH.

1 reference

12 December 2020

Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: does body weight matter?

1 reference

12 December 2020

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

12 December 2020

Effects of the mean daily doses of imatinib during the first year on survival of patients with chronic myeloid leukemia in Japan: a study of the Hokkaido Hematology Study Group

1 reference

12 December 2020

Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group

1 reference

12 December 2020

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

12 December 2020

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

1 reference

12 December 2020

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

12 December 2020

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

12 December 2020

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

12 December 2020

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

12 December 2020

Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study

1 reference

12 December 2020

Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia.

1 reference

12 December 2020

10.1007/S12185-010-0621-X

Identifiers

DOI

1 reference

12 November 2017

1 reference